Natural Biogenex completes its maiden fund-raise of Rs 18.75 Cr

The proceeds from this fund-raise will be deployed in financing the project requirements of the API business

CPhI & P-MEC India expo to encourage cost-effective solutions in India’s march towards a Rs 10.5 lakh crore pharma market by 2030

The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees

SMS Pharma revenue down 9%

Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn

Biocon Biologics features on ASIA IP ELITE List 2022

This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.

Ayu Health receives US $27 million additional funding

The company is making its entry into the Hyderabad market through its unique asset-light business model

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.